232 related articles for article (PubMed ID: 34448275)
21. Combination of CT/MRI LI-RADS with CEUS can improve the diagnostic performance for HCCs.
Zhou Y; Ding J; Qin Z; Long L; Zhang X; Wang F; Chen C; Wang Y; Zhou H; Jing X
Eur J Radiol; 2022 Apr; 149():110199. PubMed ID: 35196614
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
Kim YY; An C; Kim S; Kim MJ
Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
[TBL] [Abstract][Full Text] [Related]
23. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.
Jeon SK; Joo I; Bae JS; Park SJ; Lee JM
Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875
[TBL] [Abstract][Full Text] [Related]
24. Liver Imaging Reporting and Data System Category on Magnetic Resonance Imaging Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation Within the Milan Criteria: A Multicenter Study.
Lee S; Kim KW; Jeong WK; Jeong SY; Hwang JA; Choi JS; Lee SG; Joh JW
Ann Surg Oncol; 2021 Oct; 28(11):6782-6789. PubMed ID: 33751296
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
Huang Z; Zhou P; Li S; Li K
Eur Radiol; 2022 Oct; 32(10):7146-7154. PubMed ID: 35639147
[TBL] [Abstract][Full Text] [Related]
26. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
Lee S; Kim SS; Chang DR; Kim H; Kim MJ
Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma.
Khanna G; Chavhan GB; Schooler GR; Fraum TJ; Alazraki AL; Squires JH; Salter A; Podberesky DJ; Towbin AJ
Radiology; 2021 Apr; 299(1):190-199. PubMed ID: 33620289
[TBL] [Abstract][Full Text] [Related]
29. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
[TBL] [Abstract][Full Text] [Related]
30. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
Hassan OT; Behr SC; Ohliger MA; Fowler KJ; Gill RM; Fidelman N; Mehta N; Choi HH
Radiology; 2023 Dec; 309(3):e222776. PubMed ID: 38112541
[TBL] [Abstract][Full Text] [Related]
31. A radiogenomic analysis of hepatocellular carcinoma: association between fractional allelic imbalance rate index and the liver imaging reporting and data system (LI-RADS) categories and features.
Furlan A; Almusa O; Yu RK; Sagreiya H; Borhani AA; Bae KT; Marsh JW
Br J Radiol; 2018 Jun; 91(1086):20170962. PubMed ID: 29565672
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the Time Difference Method in Identifying Hepatocellular Carcinoma in Current CEUS LR-M Category Nodules.
Shao LJ; Wang YJ; Yin SS; Jiang BB; Liu YH; Wang JC; Yang W; Wu W; Yan K
Ultrasound Med Biol; 2024 Apr; 50(4):502-508. PubMed ID: 38246805
[TBL] [Abstract][Full Text] [Related]
33. Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound.
Huang H; Li CQ; He DN; Ruan SM; Li MD; Cheng MQ; Lu MD; Kuang M; Wang W; Wang Y; Chen LD
Eur Radiol; 2023 Dec; 33(12):9336-9346. PubMed ID: 37405501
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
[No Abstract] [Full Text] [Related]
35. Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma.
Kim HD; Song GW; Shim JH; Han S; An J; Moon DB; Kim KM; Lim YS; Ko GY; Hwang S; Lee HC; Yu E; Sung KB; Lee SG
Hepatol Int; 2017 Mar; 11(2):209-219. PubMed ID: 28144812
[TBL] [Abstract][Full Text] [Related]
36. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.
Chaudhry M; McGinty KA; Mervak B; Lerebours R; Li C; Shropshire E; Ronald J; Commander L; Hertel J; Luo S; Bashir MR; Burke LMB
Radiology; 2020 Feb; 294(2):320-326. PubMed ID: 31845843
[TBL] [Abstract][Full Text] [Related]
37. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
38. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
[TBL] [Abstract][Full Text] [Related]
39. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade.
Cheng MQ; Hu HT; Huang H; Pan JM; Xian MF; Huang Y; Kuang M; Xie XY; Li W; Wang W; Lu MD
Eur Radiol; 2021 Aug; 31(8):5680-5688. PubMed ID: 33502556
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
